# Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

> **NCT00120835** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** valopicitabine
- **DRUG:** pegylated interferon

## Key facts

- **NCT ID:** NCT00120835
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00120835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00120835, "Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00120835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*